Immunome Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Immunome Inc. filed its 10-Q for Q1 2024, detailing equity transactions, licensing agreements, and subsequent events.</b>

AI Summary

Immunome Inc. (IMNM) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Immunome Inc. reported financial results for the quarter ended March 31, 2024. The company's filing includes details on common stock and additional paid-in capital transactions. Key events during the period include an IPO and a license agreement with Zentalis Pharmaceuticals Inc. Subsequent events noted are an open market sale and a purchase agreement with Ayala. Financial data presented covers retained earnings, accumulated other comprehensive income, and equity incentive plans.

Why It Matters

For investors and stakeholders tracking Immunome Inc., this filing contains several important signals. This filing provides investors with a quarterly update on Immunome's financial health and strategic partnerships. Understanding these transactions is crucial for assessing the company's capital structure and future growth potential.

Risk Assessment

Risk Level: — Immunome Inc. shows moderate risk based on this filing. The company is in the pharmaceutical preparations industry, which is highly competitive and subject to significant regulatory oversight, posing inherent risks to its financial performance and market position.

Analyst Insight

Investors should monitor Immunome's progress on its licensing agreements and any further equity transactions to gauge its financial stability and growth trajectory.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q Filing)
• 2024-05-14 — Filing Date (10-Q Filing)
• 2024-02-29 — IPO Date (Subsequent Event)

Key Players & Entities

• Immunome Inc. (company) — Filer
• Zentalis Pharmaceuticals Inc. (company) — License Agreement
• Ayala (company) — Purchase Agreement
• Abbvie (company) — Collaboration Agreement

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive regulation by government authorities, which can impact product development, approval, and marketing.
• Market Competition [medium — market]: The company operates in a highly competitive market with numerous other companies developing similar therapies.
• Funding Needs [medium — financial]: The company may require additional funding to support its ongoing research and development activities.

Industry Context

Immunome Inc. operates in the biotechnology sector, focusing on the development of therapeutics. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles.

Regulatory Implications

The pharmaceutical and biotechnology industries are heavily regulated by bodies like the FDA, requiring strict adherence to guidelines for drug development, clinical trials, and manufacturing.

What Investors Should Do

1. Review Immunome's detailed financial statements for Q1 2024.
2. Analyze the impact of the IPO and subsequent equity transactions on the company's capital structure.
3. Track the progress and outcomes of the licensing and collaboration agreements mentioned in the filing.

Key Dates

• 2024-03-31: Quarterly Period End — Financial reporting for Q1 2024
• 2024-05-14: Filing Date — Submission of 10-Q report
• 2024-02-29: IPO Completion — Significant equity event

Year-Over-Year Comparison

This 10-Q filing provides the first comprehensive look at Immunome's financial position and key transactions following its IPO in February 2024.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value IMNM The Nasdaq Capital M

Filing Documents

• tmb-20240331x10q.htm (10-Q) — 1511KB
• tmb-20240331xex1d1.htm (EX-1.1) — 283KB
• tmb-20240331xex5d1.htm (EX-5.1) — 12KB
• tmb-20240331xex31d1.htm (EX-31.1) — 14KB
• tmb-20240331xex31d2.htm (EX-31.2) — 14KB
• tmb-20240331xex32d1.htm (EX-32.1) — 8KB
• tmb-20240331xex32d2.htm (EX-32.2) — 8KB
• tmb-20240331xex1d1002.jpg (GRAPHIC) — 1KB
• tmb-20240331xex5d1001.jpg (GRAPHIC) — 6KB
• 0001558370-24-008066.txt (&nbsp;) — 6259KB
• tmb-20240331.xsd (EX-101.SCH) — 47KB
• tmb-20240331_cal.xml (EX-101.CAL) — 41KB
• tmb-20240331_def.xml (EX-101.DEF) — 164KB
• tmb-20240331_lab.xml (EX-101.LAB) — 376KB
• tmb-20240331_pre.xml (EX-101.PRE) — 311KB
• tmb-20240331x10q_htm.xml (XML) — 759KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) - Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 3 - Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023 4 - Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three Months Ended March 31, 2024 and 2023 5 - Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 6 - Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 20 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk. 29 Item 4.

Controls and Procedures

Controls and Procedures. 30

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1. Legal Proceedings. 30 Item 1A. Risk Factors. 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 92 Item 3. Defaults Upon Senior Securities. 92 Item 4. Mine and Safety Disclosures. 92 Item 5. Other Information. 92 Item 6. Exhibits. 93

SIGNATURES

SIGNATURES 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. IMMUNOME, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (unaudited) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 269,723 $ 98,679 Marketable securities 39,983 39,463 Prepaid expenses and other current assets 3,620 6,561 Total current assets 313,326 144,703 Property and equipment, net 4,302 2,073 Operating right-of-use assets 1,458 1,564 Restricted cash 100 100 Other long-term assets 568 100 Total assets $ 319,754 $ 148,540 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 7,179 $ 3,311 Accrued expenses and other current liabilities 10,844 8,025 Deferred revenue, current 12,745 10,493 Total current liabilities 30,768 21,829 Deferred revenue, non-current 2,208 5,489 Operating lease liabilities, net of current portion 1,206 1,340 Total liabilities 34,182 28,658 Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2024 and December 31, 2023 — — Common stock, $ 0.0001 par value; 300,000,000 and 200,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 59,694,243 and 43,251,778 shares issued and outstanding at March 31, 2024 and December 31, 2023 , respectively 6 4 Additional paid-in capital 637,861 342,663 Accumulated other comprehensive income 4 22 Accumulated deficit ( 352,299 ) ( 222,807 ) Total stockholders' equity 285,572 119,882 Total liabilities and stockholders' equity $ 319,754 $ 148,540 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements . 3 Table of Contents IMMUNOME, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per

View Full Filing

View this 10-Q filing on SEC EDGAR